Demographic and treatment-related risk factors for infections after 2 and 5 years among HCT survivors, analyzed separately by allogeneic and autologous donor status
| . | Infections ≥2-y: IRR (95% CI)* . | Infections ≥5-y: IRR (95% CI)† . | ||||
|---|---|---|---|---|---|---|
| Infection type/organ system . | Allogeneic: cGVHD vs none . | Allogeneic: original disease relapse vs none . | Autologous: original disease relapse vs none . | Allogeneic: cGVHD vs none . | Allogeneic: original disease relapse vs none . | Autologous: original disease relapse vs none . |
| Infection | ||||||
| All | 1.6 (0.9-2.8) | 2.8 (1.7-4.6) | 3.9 (2.4-5.5) | 1.0 (0.4-2.4) | 1.1 (0.5-2.6) | 4.0 (2.2-7.3) |
| Sepsis, any | 1.9 (1.0-3.8) | 2.8 (1.4-5.8) | 3.4 (1.9-6.1) | 1.6 (0.5-5.5) | 1.3 (0.4-4.7) | 3.1 (1.2-7.5) |
| Bacterial infections | 1.6 (0.9-2.9) | 2.5 (1.4-4.6) | 3.7 (2.3-5.8) | 1.2 (0.5-3.4) | 1.3 (0.5-3.3) | 3.7 (1.9-7.1) |
| Staphylococcus | 2.0 (0.6-6.5) | 2.1 (0.8-5.7) | 2.4 (1.0-5.5) | 1.8 (0.6-5.7) | 0.9 (0.2-4.0) | 1.9 (0.6-5.7) |
| Streptococcus | 1.2 (0.5-3.3) | 3.9 (1.4-11.0) | 7.6 (3.6-16.0) | 4.9 (0.6-37.6) | 2.5 (0.5-11.4) | 22.3 (4.0-124.9) |
| Gram negative | 2.8 (0.9-8.5) | 1.6 (0.4-6.0) | 3.9 (1.8-8.3) | 1.6 (0.4-7.2) | ‡ | 2.6 (0.9-7.8) |
| Fungal infections | 1.3 (0.6-2.8) | 4.5 (2.4-8.5) | 4.5 (2.0-9.9) | 0.6 (0.2-1.7) | 1.0 (0.2-4.6) | 4.0 (1.3-12.1) |
| Candida | 1.6 (0.6-4.2) | 7.1 (3.2-15.4) | 3.5 (1.4-8.5) | 0.9 (0.2-3.2) | 1.2 (0.2-8.2) | 5.8 (1.7-20.3) |
| Non-Candida | 1.0 (0.4-2.7) | 3.1 (1.3-7.3) | 6.4 (2.1-19.6) | 0.3 (0.1-1.3) | 0.7 (0.1-3.8) | 2.4 (0.3-17.5) |
| Aspergillus | 0.9 (0.2-3.2) | 3.5 (1.3-9.8) | 5.2 (1.1-25.5) | 0.2 (0.0-1.0) | 0.7 (0.1-5.7) | 1.4 (0.1-27.4) |
| Viral infections | 2.4 (1.1-5.3) | 1.1 (0.5-2.7) | 2.8 (1.2-6.1) | 1.0 (0.3-3.6) | 0.6 (0.1-3.8) | 3.8 (1.2-11.5) |
| Cytomegalovirus | 0.6 (0.1-2.7) | 0.7 (0.1-5.9) | ‡ | 0.1 (0.0-1.2) | ‡ | 0.9 (0.1-9.5) |
| H simplex and V zoster | 3.2 (0.9-11.5) | 2.0 (0.6-6.2) | 6.5 (2.6-16.2) | 1.4 (0.2-11.2) | ‡ | 4.7 (0.9-24.3) |
| Organ system | ||||||
| Nervous/sensory | 4.1 (0.8-22.0) | 3.7 (0.9-16.2) | 19.0 (3.8-96.5) | ‡ | 2.8 (0.4-22.4) | ‡ |
| Respiratory | 1.4 (0.8-2.6) | 2.5 (1.5-4.1) | 2.5 (1.5-4.1) | 0.8 (0.3-2.1) | 0.9 (0.4-2.2) | 3.0 (1.5-6.2) |
| Bacterial pneumonia | 2.2 (1.0-4.9) | 1.7 (0.7-4.1) | 3.6 (1.6-8.3) | 2.0 (0.6-6.6) | 1.7 (0.5-6.1) | 3.8 (0.9-15.4) |
| Fungal pneumonia | 1.0 (0.3-2.9) | 3.0 (1.1-8.5) | 3.1 (0.8-12.6) | 0.2 (0.0-1.1) | 0.7 (0.1-5.4) | ‡ |
| Viral pneumonia | 2.0 (0.6-7.0) | 2.0 (0.6-6.8) | 0.9 (0.1-7.3) | 0.6 (0.2-2.5) | 1.0 (0.1-7.9) | ‡ |
| Pneumonia, NOS | 1.5 (0.7-3.3) | 2.5 (1.3-4.8) | 2.3 (1.2-4.2) | 0.7 (0.2-2.3) | 0.8 (0.3-2.7) | 2.6 (1.1-6.0) |
| Gastrointestinal | 1.4 (0.5-3.6) | 2.6 (1.0-7.0) | 2.1 (0.7-6.0) | 1.0 (0.3-3.6) | 1.5 (0.3-8.3) | 3.6 (0.8-17.1) |
| Genitourinary | 2.7 (1.0-6.8) | 1.4 (0.4-4.7) | 2.1 (0.8-5.2) | 2.4 (0.6-8.6) | ‡ | 3.3 (0.6-17.8) |
| Musculoskeletal | 1.4 (0.3-8.1) | 1.0 (0.1-7.6) | ‡ | 0.4 (0.0-8.6) | ‡ | 2.4 (0.3-19.0) |
| Skin | 1.8 (0.7-4.7) | 1.9 (0.7-4.9) | 0.9 (0.2-3.7) | 1.7 (0.5-5.8) | 0.7 (0.1-5.4) | 0.9 (0.1-6.8) |
| Vaccine-preventable, all | 2.9 (1.3-6.6) | 1.2 (0.5-2.9) | 3.6 (1.7-7.6) | 3.0 (0.8-10.8) | 1.5 (0.5-4.9) | 6.3 (1.9-21.1) |
| Vaccine-preventable, limited§ | 2.9 (1.0-8.6) | 0.8 (0.2-2.9) | 2.8 (1.1-7.1) | 3.2 (0.6-17.0) | 1.1 (0.2-6.9) | 5.6 (1.5-20.5) |
| . | Infections ≥2-y: IRR (95% CI)* . | Infections ≥5-y: IRR (95% CI)† . | ||||
|---|---|---|---|---|---|---|
| Infection type/organ system . | Allogeneic: cGVHD vs none . | Allogeneic: original disease relapse vs none . | Autologous: original disease relapse vs none . | Allogeneic: cGVHD vs none . | Allogeneic: original disease relapse vs none . | Autologous: original disease relapse vs none . |
| Infection | ||||||
| All | 1.6 (0.9-2.8) | 2.8 (1.7-4.6) | 3.9 (2.4-5.5) | 1.0 (0.4-2.4) | 1.1 (0.5-2.6) | 4.0 (2.2-7.3) |
| Sepsis, any | 1.9 (1.0-3.8) | 2.8 (1.4-5.8) | 3.4 (1.9-6.1) | 1.6 (0.5-5.5) | 1.3 (0.4-4.7) | 3.1 (1.2-7.5) |
| Bacterial infections | 1.6 (0.9-2.9) | 2.5 (1.4-4.6) | 3.7 (2.3-5.8) | 1.2 (0.5-3.4) | 1.3 (0.5-3.3) | 3.7 (1.9-7.1) |
| Staphylococcus | 2.0 (0.6-6.5) | 2.1 (0.8-5.7) | 2.4 (1.0-5.5) | 1.8 (0.6-5.7) | 0.9 (0.2-4.0) | 1.9 (0.6-5.7) |
| Streptococcus | 1.2 (0.5-3.3) | 3.9 (1.4-11.0) | 7.6 (3.6-16.0) | 4.9 (0.6-37.6) | 2.5 (0.5-11.4) | 22.3 (4.0-124.9) |
| Gram negative | 2.8 (0.9-8.5) | 1.6 (0.4-6.0) | 3.9 (1.8-8.3) | 1.6 (0.4-7.2) | ‡ | 2.6 (0.9-7.8) |
| Fungal infections | 1.3 (0.6-2.8) | 4.5 (2.4-8.5) | 4.5 (2.0-9.9) | 0.6 (0.2-1.7) | 1.0 (0.2-4.6) | 4.0 (1.3-12.1) |
| Candida | 1.6 (0.6-4.2) | 7.1 (3.2-15.4) | 3.5 (1.4-8.5) | 0.9 (0.2-3.2) | 1.2 (0.2-8.2) | 5.8 (1.7-20.3) |
| Non-Candida | 1.0 (0.4-2.7) | 3.1 (1.3-7.3) | 6.4 (2.1-19.6) | 0.3 (0.1-1.3) | 0.7 (0.1-3.8) | 2.4 (0.3-17.5) |
| Aspergillus | 0.9 (0.2-3.2) | 3.5 (1.3-9.8) | 5.2 (1.1-25.5) | 0.2 (0.0-1.0) | 0.7 (0.1-5.7) | 1.4 (0.1-27.4) |
| Viral infections | 2.4 (1.1-5.3) | 1.1 (0.5-2.7) | 2.8 (1.2-6.1) | 1.0 (0.3-3.6) | 0.6 (0.1-3.8) | 3.8 (1.2-11.5) |
| Cytomegalovirus | 0.6 (0.1-2.7) | 0.7 (0.1-5.9) | ‡ | 0.1 (0.0-1.2) | ‡ | 0.9 (0.1-9.5) |
| H simplex and V zoster | 3.2 (0.9-11.5) | 2.0 (0.6-6.2) | 6.5 (2.6-16.2) | 1.4 (0.2-11.2) | ‡ | 4.7 (0.9-24.3) |
| Organ system | ||||||
| Nervous/sensory | 4.1 (0.8-22.0) | 3.7 (0.9-16.2) | 19.0 (3.8-96.5) | ‡ | 2.8 (0.4-22.4) | ‡ |
| Respiratory | 1.4 (0.8-2.6) | 2.5 (1.5-4.1) | 2.5 (1.5-4.1) | 0.8 (0.3-2.1) | 0.9 (0.4-2.2) | 3.0 (1.5-6.2) |
| Bacterial pneumonia | 2.2 (1.0-4.9) | 1.7 (0.7-4.1) | 3.6 (1.6-8.3) | 2.0 (0.6-6.6) | 1.7 (0.5-6.1) | 3.8 (0.9-15.4) |
| Fungal pneumonia | 1.0 (0.3-2.9) | 3.0 (1.1-8.5) | 3.1 (0.8-12.6) | 0.2 (0.0-1.1) | 0.7 (0.1-5.4) | ‡ |
| Viral pneumonia | 2.0 (0.6-7.0) | 2.0 (0.6-6.8) | 0.9 (0.1-7.3) | 0.6 (0.2-2.5) | 1.0 (0.1-7.9) | ‡ |
| Pneumonia, NOS | 1.5 (0.7-3.3) | 2.5 (1.3-4.8) | 2.3 (1.2-4.2) | 0.7 (0.2-2.3) | 0.8 (0.3-2.7) | 2.6 (1.1-6.0) |
| Gastrointestinal | 1.4 (0.5-3.6) | 2.6 (1.0-7.0) | 2.1 (0.7-6.0) | 1.0 (0.3-3.6) | 1.5 (0.3-8.3) | 3.6 (0.8-17.1) |
| Genitourinary | 2.7 (1.0-6.8) | 1.4 (0.4-4.7) | 2.1 (0.8-5.2) | 2.4 (0.6-8.6) | ‡ | 3.3 (0.6-17.8) |
| Musculoskeletal | 1.4 (0.3-8.1) | 1.0 (0.1-7.6) | ‡ | 0.4 (0.0-8.6) | ‡ | 2.4 (0.3-19.0) |
| Skin | 1.8 (0.7-4.7) | 1.9 (0.7-4.9) | 0.9 (0.2-3.7) | 1.7 (0.5-5.8) | 0.7 (0.1-5.4) | 0.9 (0.1-6.8) |
| Vaccine-preventable, all | 2.9 (1.3-6.6) | 1.2 (0.5-2.9) | 3.6 (1.7-7.6) | 3.0 (0.8-10.8) | 1.5 (0.5-4.9) | 6.3 (1.9-21.1) |
| Vaccine-preventable, limited§ | 2.9 (1.0-8.6) | 0.8 (0.2-2.9) | 2.8 (1.1-7.1) | 3.2 (0.6-17.0) | 1.1 (0.2-6.9) | 5.6 (1.5-20.5) |
NOS, not otherwise specified.
Models adjusted for sex, race/ethnicity, age, transplantation year, donor type, cGVHD status, and history of posttransplantation relapse (within the first 2 years).
Models similarly adjusted as ≥2-year outcomes, except that history of posttransplantation relapse was expanded to events occurring within the first 5 years.
Five events or fewer. Estimates are unstable and models do not converge.
If hepatitis B and V zoster are excluded.